Baird Medical Investment Holdings Limited (BDMDW) Aandelenanalyse

Bedrijfsoverzicht

Baird Medical Investment Holdings Limited is a specialized entity focused on the research, development, manufacturing, and sales of microwave ablation devices within the People's Republic of China. Although specific sector and industry classifications are not publicly disclosed in the available data, the company operates within the broader medical technology landscape by offering microwave ablation apparatus and needles, along with long microwave ablation solutions. The company employs a workforce of 143 individuals to support its operations across China. While precise market capitalization figures are unavailable in the current dataset, the company reported a trailing twelve-month revenue of $31.86 million, which places it in a niche position relative to its operational scale. The absence of a disclosed market cap suggests the company may be listed on a market with limited liquidity or where valuation multiples are not standardly reported alongside traditional equity metrics, indicating a distinct positioning in the Chinese medical device market that relies heavily on operational revenue rather than public market valuation for its primary economic assessment.

Financiële gezondheid

The company generated $31.86 million in revenue over the trailing twelve months, yet it reported a net income loss of $-3,170,793, highlighting a significant disparity between top-line activity and bottom-line profitability. Despite this net loss, the company maintains a positive EBITDA of $919,415, suggesting that while non-operating expenses or interest costs are substantial, core operational cash generation before interest and taxes remains positive. This divergence between net income and EBITDA reveals a cost structure burdened by significant financial charges or non-operating items that erode reported earnings despite underlying operational viability. The firm possesses $2.50 million in cash reserves, which provides a limited buffer against its total debt load of $22.56 million, indicating a reliance on external financing for operations. The company's debt-to-equity ratio stands at 63.33, a figure that points to a highly leveraged balance sheet where debt obligations significantly outweigh equity capitalization. However, the current ratio of 1.71 suggests that the company holds sufficient current assets to cover its short-term liabilities, implying a manageable level of immediate liquidity risk. Return on Equity is negative at -8.0%, and Return on Assets is -0.2%, metrics that collectively indicate that management has not yet generated returns that exceed the cost of capital or the opportunity cost of deployed assets. These negative return figures reflect the company's current stage of development or the high fixed costs associated with its manufacturing and R&D activities in the Chinese market.

Waarderingsbeoordeling

Trailing P/E and forward P/E ratios are not applicable due to the company's negative earnings, which prevents the calculation of standard price-to-earnship multiples. Consequently, the price-to-book ratio serves as a primary valuation anchor, standing at 0.07, which indicates that the market values the company's equity at just 7% of its book value, reflecting a deep discount relative to the net asset position. The price-to-sales ratio and EV/EBITDA multiples are similarly unavailable in the provided data, limiting the ability to compare the firm's valuation against peers using traditional sales or enterprise value metrics. Regarding trading range, the 52-week high is recorded at $0.10 and the 52-week low is also $0.10, indicating that the stock has traded within a static range where the current price sits at 0% deviation from both the high and low points. A beta of -1.16 is reported, which is an anomalous metric suggesting an inverse correlation to the broader market or a data anomaly, as a negative beta implies the stock moves opposite to the market rather than exhibiting standard volatility characteristics. The static 52-week range and the negative beta highlight the unique risk profile and lack of price momentum associated with this specific equity instrument.

Growth & Income

Revenue growth year-over-year has declined by 39.4%, while earnings growth data is not available due to the company's current unprofitability. This contraction in revenue suggests a challenging operating environment or a deliberate shift in sales strategy within the Chinese market, whereas the lack of earnings growth data is a direct result of the negative net income rather than a lack of performance tracking. As the company does not pay a dividend, evidenced by the non-applicable dividend yield and payout ratio, all available cash flows are theoretically retained for reinvestment into operations rather than distribution to shareholders. The absence of a dividend payout ratio further underscores the company's focus on capital retention, which is typical for firms in the research and development phase that require funding for their microwave ablation product lines. The overall growth and income profile is characterized by significant revenue contraction, a lack of current profitability, and zero dividend distribution, presenting a capital-intensive investment case reliant on future operational improvements to restore positive cash conversion and earnings potential.